NewAmsterdam Pharma Co N.V.'s Chief Accounting Officer Sells 8,269 Shares

NewAmsterdam Pharma Co N.V.[NAMS] has announced that Chief Accounting Officer Kooij Louise Frederika has executed a sale of 8269 shares at a price per share of $24.86 on August 25, 2025.

NewAmsterdam Pharma Co N.V. [NAMS] has announced that Chief Accounting Officer Kooij Louise Frederika has executed a sale of 8,269 shares at a price per share of $24.86 on August 25, 2025. This transaction follows a series of positive developments for the company, including recent analyst upgrades and a strategic partnership with Piramal Pharma Solutions.

The sale of shares by the CFO, a key executive in the company, may be seen as a sign of confidence in the company's prospects or a strategic move to diversify personal holdings. However, the exact reasons for the sale are not specified in the announcement.

Investors have been closely following NewAmsterdam Pharma's progress, particularly in relation to its CETP inhibitor, obicetrapib. Wells Fargo initiated coverage on the stock with an Overweight rating and a $45.00 price target, citing the drug's potential to reduce major adverse cardiovascular events (MACE) and its strong clinical trial results [1]. Additionally, the company has been making significant strides in its commercialization efforts, including a recent investment in a dedicated oral solid dosage (OSD) suite at Piramal Pharma Solutions' Sellersville facility [2].

Despite these positive developments, NewAmsterdam Pharma faces challenges, including the extended timeline for key trial results expected in late 2026. Goldman Sachs initiated coverage with a Neutral rating and a $27.00 price target, citing this extended timeline [1]. The company's ability to navigate these challenges and deliver on its clinical and commercial promises will be key to maintaining investor confidence.

References:
[1] https://www.investing.com/news/analyst-ratings/newamsterdam-pharma-stock-initiated-at-overweight-by-wells-fargo-93CH-4208426
[2] https://www.nasdaq.com/press-release/piramal-pharma-solutions-and-newamsterdam-pharma-invest-dedicated-suite-enhance-oral